GC Biopharma gains domestic approval for Hunter syndrome treatment; 'expands treatment options'
Predicted impact: Medium
Domestic approval of a new drug; the BioMarin licence worth up to ₩650B is about 33% of revenue, so meaningful.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.